ECOR Stock Overview
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
electroCore, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.58 |
| 52 Week High | US$8.08 |
| 52 Week Low | US$3.83 |
| Beta | 0.93 |
| 1 Month Change | -8.37% |
| 3 Month Change | -26.09% |
| 1 Year Change | -16.59% |
| 3 Year Change | -79.56% |
| 5 Year Change | -94.14% |
| Change since IPO | -98.13% |
Recent News & Updates
Recent updates
electroCore sees Q3 revenue below consensus
Oct 14electroCore is issued 4 new U.S. patents in nVNS therapy
Sep 21electroCore sees Q2 revenue estimate higher than consensus
Jul 12We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth
Apr 29
electroCore: Pioneering Bioelectronic Medicine
Jan 06electroCore completes sale of $1.4M of NOL tax benefits
Jun 09Do Institutions Own electroCore, Inc. (NASDAQ:ECOR) Shares?
Feb 19
electroCore expects FY20 revenue at upper end of $3.3M to $3.5M
Jan 11electroCore (NASDAQ:ECOR) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 07electroCore gains on distribution deal for gammaCore Sapphire in Eastern Europe
Dec 22electroCore shares jump 9% on positive results in migraine prevention study
Dec 08electroCore (ECOR) Investor Presentation - Slideshow
Nov 20Shareholder Returns
| ECOR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.09% | 1.8% | 1.2% |
| 1Y | -16.6% | -0.5% | 24.9% |
Price Volatility
| ECOR volatility | |
|---|---|
| ECOR Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: ECOR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 68 | Dan Goldberger | www.electrocore.com |
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance.
electroCore, Inc. Fundamentals Summary
| ECOR fundamental statistics | |
|---|---|
| Market cap | US$33.97m |
| Earnings (TTM) | -US$18.83m |
| Revenue (TTM) | US$16.03m |
2.1x
P/S Ratio-1.8x
P/E RatioIs ECOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECOR income statement (TTM) | |
|---|---|
| Revenue | US$16.03m |
| Cost of Revenue | US$2.80m |
| Gross Profit | US$13.23m |
| Other Expenses | US$32.06m |
| Earnings | -US$18.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.14 |
| Gross Margin | 82.51% |
| Net Profit Margin | -117.49% |
| Debt/Equity Ratio | 0% |
How did ECOR perform over the long term?
See historical performance and comparison